Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Leuk Lymphoma. 2018 Sep 20;60(3):583–597. doi: 10.1080/10428194.2018.1504937

Figure 1. Approach to management of primary refractory AML.

Figure 1.

Our approach to primary refractory AML takes into account patient eligibility for allogeneic HSCT and salvage chemotherapy, clinical trial availability, and molecular mutation status.

Abbreviations: AML, acute myeloid leukemia; HLA, human leukocyte antigen; FLT3-ITD, fms-like tyrosine kinase 3-internal tandem duplication; HSCT, hematopoietic stem cell transplantation; HMA, hypomethylating agent; LDAC, low-dose cytarabine